A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK5784283 (Felcorekibart) as an Add-On Therapy in Adults and Adolescents With Uncontrolled Asthma (PERSIST ASTHMA-1)
Sponsor study identifier
Secondary identifiers
REGISTRY · EU CT Number
interventional
514
1 country
1
Study Start
August 27, 2026
Actual (reported)Primary Completion
February 15, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 11, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The study aims to demonstrate the superiority of GSK5784283 compared to placebo in reducing the annualized rate of clinically meaningful asthma exacerbations.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 11, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 19, 2026
Actual (reported)August 21, 2026
Actual (reported)August 27, 2026
Actual (reported)February 15, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
October 11, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Annualized rate of clinically significant asthma exacerbations
A clinically significant exacerbation is defined as a worsening of asthma symptoms requiring the use of systemic corticosteroids or in-patient hospitalization (that is greater than or equal to \[\>=\] 24 hours) due to asthma.
Up to Week 52
Change from Baseline in pre-Bronchodilator Forced expiratory volume in 1 second (FEV1)
Baseline and at Week 52
Time to first clinically significant asthma exacerbation
Up to Week 52
Change from Baseline in Asthma Control Questionnaire-5 (ACQ-5) score
Baseline and at Week 52
Change from Baseline in Asthma Quality of Life Questionnaire (AQLQ) score
Baseline and at Week 52
Annualized rate of clinically significant exacerbations requiring emergency department (EmD) visit or hospitalization
Up to Week 52
GSK5784283 will be administered.
Placebo will be administered.
GSK Investigational Site
Miami Lakes, Florida, 33014-2479, United States
GSK Clinical Trials
GlaxoSmithKline
First Submitted
August 19, 2026
First Posted
August 21, 2026
Study Start
August 27, 2026
Actual (reported)Primary Completion
February 15, 2029
EstimatedStandard of care will be administered.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 11, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 25, 2026
Record last verified: 2026-09
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: